Home › Research › Drug development
Repurposing probucol for prevention of dementia: a nationwide cohort study
Takechi R, Dunne J, Lam V, Stephan BM, Pereira G, Clarnette R, Watts GF, Flicker L et al.. Research Square, 2026-08-13
Topic: Drug trials: efficacy and safety
Plain-language summary
Background Effective treatments for neurodegenerative disease remain elusive, highlighting the importance of prevention. Probucol, a lipid-lowering antioxidant, is neuroprotective in preclinical models but untested for dementia in large populations. Methods Using the Japan Medical Data Centre claims database (2014–2023), adults aged ≥ 50 years prescribed probucol or statins were identified. Propensity score matching produced a stacked cohort of 52,532 individuals. Conditional logistic regression estimated odds ratios (ORs) for incident all-cause dementia and subtypes, adjusted for age and sex; stratified Cox models accounted for follow-up time. Results Probucol use was associated with approximately 51% lower odds of all-cause dementia than statins combined (adjusted OR 0.48, 95% CI 0.45–0.53). Associations were consistent across statins (adjusted ORs 0.40–0.66), Alzheimer’s disease, and vascular dementia. Sensitivity analyses were comparable (adjusted HR 0.50, 95% CI 0.45–0.56). Conclusions In this nationwide cohort, probucol use was associated with substantially lower dementia risk than statins, supporting evaluation of probucol for repurposing in dementia prevention.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Takechi, R., Dunne, J., Lam, V., Stephan, B. M., Pereira, G., Clarnette, R., et al. (2026). Repurposing probucol for prevention of dementia: a nationwide cohort study. Research Square. https://doi.org/10.21203/rs.3.rs-10311061/v1
Vancouver
Takechi R, Dunne J, Lam V, Stephan BM, Pereira G, Clarnette R, et al. Repurposing probucol for prevention of dementia: a nationwide cohort study. Research Square. 2026. doi:10.21203/rs.3.rs-10311061/v1.
BibTeX
@article{takechi2026-25853c66,
author = {Takechi, R. and Dunne, J. and Lam, V. and Stephan, B. M. and Pereira, G. and Clarnette, R. and Watts, G. F. and Flicker, L. and others},
title = {{Repurposing probucol for prevention of dementia: a nationwide cohort study}},
journal = {Research Square},
year = {2026},
doi = {10.21203/rs.3.rs-10311061/v1},
url = {https://doi.org/10.21203/rs.3.rs-10311061/v1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Probucol use was associated with approximately 51% lower odds of all-cause dementia than statins combined (adjusted OR 0.48, 95% CI 0.45–0.53).
- Conclusions In this nationwide cohort, probucol use was associated with substantially lower dementia risk than statins, supporting evaluation of probucol for repurposing in dementia prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants52,532
- Effect sizeOR 0.48; HR 0.50
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 40 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 62 points we could judge it on, which is 40 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Research Square) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 52,532 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 25 of the 62 points we could judge it on is 40 out of 100. |
| Total | 40 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “metabolic-syndrome”
306 studies in the library carry the topic tag “metabolic-syndrome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 306 tagged studies.